Enochian Biosciences, Inc. (ENOB): Price and Financial Metrics
ENOB Price/Volume Stats
| Current price | $0.70 | 52-week high | $2.99 |
| Prev. close | $0.70 | 52-week low | $0.39 |
| Day low | $0.70 | Volume | 88,300 |
| Day high | $0.75 | Avg. volume | 137,347 |
| 50-day MA | $0.64 | Dividend yield | N/A |
| 200-day MA | $1.13 | Market Cap | 40.80M |
ENOB Stock Price Chart Interactive Chart >
Enochian Biosciences, Inc. (ENOB) Company Bio
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.
Latest ENOB News From Around the Web
Below are the latest news stories about ENOCHIAN BIOSCIENCES INC that investors may wish to consider to help them evaluate ENOB as an investment opportunity.
Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder MeetingLOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise that its 2023 Annual Stockholder Meeting (the “Annual Meeting”), which was scheduled to be held yesterday, June 22, 2023 at 12:00 p.m. Eastern Time, was convened and adjourned, without any business being conducted, due to the lack of the required quorum. As a result of the required quorum not being p |
Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA ReviewLOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company’s Pre-IND submission. If successful, that would allow clinical trials to begin by the first half of 2024. The Company’s proprietary, novel technology uses cell- |
Enochian BioSciences’ CEO Letter to ShareholdersTurning the Page; A Promising FutureLOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Accelerated Pre-Investigational New Drug (Pre-IND) submission to the US Food and Drug Administration (FDA) for potential cancer product due to additional promising results from studies in a commonly used mouse modelDr. Anahid Jewett, a leading cancer researcher from the University of California, Los Angeles (UCLA) presented key results at the 8th Annual Innate Killer Summit last week (Link to pr |
Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading ResearcherLOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles (UCLA). The experiments demonstrated highly significant reductions in the weight and volume of pancreatic tumors following therapy |
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing RequirementsLOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms 10-Q for the quarters ending September 30, 2022 and December 31, 2022 on March 7th and March 9th, 2023, respectively. “I am very pleased that the Company is once again compliant with the NASDAQ listing requirem |
ENOB Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -44.00% |
| 3-year | -80.72% |
| 5-year | -88.43% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -85.87% |
| 2021 | 147.12% |
| 2020 | -41.24% |
| 2019 | -28.29% |
Loading social stream, please wait...